Fusion Antibodies Share Discussion Threads

[donald_tramp] 06/3/2019 19:17

After a challenging first six months and disappointing revenues in H1 FY 2019, order levels picked up significantly from October 2018 onwards such that revenues in H2 FY 2019 are expected to exceed all previous six-month periods. Total orders received in H2 FY 2019 to date have exceeded GBP1.9 million (H1 2019: GBP1.2m, H2 2018: GBP0.8 million) with more in the pipeline. In excess of GBP1.1 million of these orders will not be fulfilled and therefore recognised until the next financial year. The Company remains in a strong cash position, with net cash in excess of GBP2.0 million. This figure is not expected to materially change prior to the year end.

[pireric] 01/12/2018 16:56

Amazing how bad this has been since IPO

[fillipe] 25/9/2018 16:12

FAB - moves very well on any buys and indeed there is buy interest being shown at these bargain prices.
The best route to quantity at a reasonable price is to pick up stock gradually.

f

[fillipe] 24/9/2018 19:46

Good to see this FAB Dir buy.



f

[opodio] 28/8/2018 07:06

How much cash left?

[fhasson] 16/8/2018 09:44

Not able to buy any on HL , anyone else having same problem?

[fhasson] 13/8/2018 14:57

Timbo , do you think MM are at it here as those big buys are not shifting price up? What's your take? Appreciated

[timbo003] 13/8/2018 07:50

Back to the IPO price (82p) today?

I see they still state that they have 8 out of the top 10 pharmas as customers in today's RNS, so presumably the one they lost in March, is not one of the eight


For reference, Allenby's last market forecast was back in March with the share price standing at 125p/share (market cap £27.6m):

[opodio] 13/8/2018 07:10

Sales less than expected cos we lied and cheated our way to ipo

Running out of cash soon
70p today

[haroldthegreat] 20/6/2018 13:53

Only one customer exceeds 10% of income (10.4%) so worst case scenario if they left would be 10.4% lost. One doesn't know if they are that largest company .perhaps timbo has the answer to that question ?

[haroldthegreat] 20/6/2018 13:27

what % of income is from mab discovery ? Amati doubled their investment 6 weeks ago and i am sure they did due diligence before doing so.they must have known about contract renewal dates and wouldnt have purchased if this was a potential problem.

[fhasson] 06/6/2018 22:00

It's like -wall - talking - and brick

[fhasson] 06/6/2018 21:58

https://www.fusionantibodies.com/blog/2018/june/fusion-antibodies-partners-with-protein-alternatives

[fhasson] 13/5/2018 20:41

Hopefully some positive share movement with new pancreatic cancer cell antibody work with fusion and QUB

[fhasson] 13/5/2018 20:39

https://t.co/NeZxTCJEHj?amp=1

[fhasson] 03/5/2018 23:23

Appreciate your feedback timbo003 over the coming weekend and will check the website too. Good to see the past few weeks share price appears to be ticking up,which may well be down to increased business deals / interest in this emerging area of medicine. Also holding OXB in my portfolio which am very excited about and recognise FAB as being in the same chess game of chronic disease management and immuno-oncology.F

[timbo003] 03/5/2018 22:03

>>>>Fhasson

I would estimate that there were around 20 - 25 attendees and it a very informative meeting with many interesting questions during the Q&A (not just from me!). I will endeavor to write up a few notes at the weekend, meanwhile I have asked if the slide deck used last night could go up on the FAB web site although it hasn't gone up yet as far as I can see.

[fhasson] 03/5/2018 21:45

Any update on the investors meeting on Wednesday Timbo?

[walbrook2] 25/4/2018 11:32

This is a post from Walbrook PR, we provide financial PR & IR services for Fusion Antibodies. As a reminder we are organising an investor event for the Company, details below. If you would like to attend please email Walbrook PR on - [e-mail] - rather than replying to this post. Thank you.

Fusion Antibodies will be hosting an investor presentation on Wednesday 2 May 2018. The briefing by Paul Kerr, CEO of Fusion will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking.

If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email [e-mail].

[fhasson] 23/4/2018 16:23

Unfortunately cannot make it but keep us informed. Hopefully some good news awaits us!

[timbo003] 23/4/2018 11:31

I received this E mail from Walbrook this morning, I shall definitely go along


Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces that it will hold a presentation for investors on Wednesday, 2 May 2018.

The briefing by Paul Kerr, CEO of Fusion will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please reply to: [e-mail]

[wetdream] 10/4/2018 17:59

Dealers trying to attract business.
Otherwise zzzzzz